Drug Profile

Ceruloplasmin - Kedrion Biopharma

Latest Information Update: 02 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kedrion Biopharma
Class Alcohol oxidoreductases
Mechanism of Action Enzyme replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Familial apoceruloplasmin deficiency
New Molecular Entity No

Highest Development Phases

Preclinical Familial apoceruloplasmin deficiency

Most Recent Events

27 Nov 2025 Ceruloplasmin - Kedrion Biopharma receives Orphan Drug status for Familial apoceruloplasmin deficiency in European Union
07 Aug 2025 Ceruloplasmin - Kedrion Biopharma receives Orphan Drug status for Familial apoceruloplasmin deficiency in USA
30 Jan 2024 Preclinical trials in Familial apoceruloplasmin deficiency in USA (Intraperitoneal)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com